1
|
Zhang A, Seiss K, Laborde L, Palacio-Ramirez S, Guthy D, Lanter M, Lorber J, Vulpetti A, Arista L, Zoller T, Radimerski T, Thoma C, Hebach C, Tschantz WR, Karpov A, Hollingworth GJ, D'Alessio JA, Ferretti S, Burger MT. Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates. Bioconjug Chem 2024; 35:140-146. [PMID: 38265691 DOI: 10.1021/acs.bioconjchem.3c00535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2024]
Abstract
Antibody-drug conjugates (ADCs) are an established modality that allow for targeted delivery of a potent molecule, or payload, to a desired site of action. ADCs, wherein the payload is a targeted protein degrader, are an emerging area in the field. Herein we describe our efforts of delivering a Bruton's tyrosine kinase (BTK) bifunctional degrader 1 via a CD79b mAb (monoclonal antibody) where the degrader is linked at the ligase binding portion of the payload via a cleavable linker to the mAb. The resulting CD79b ADCs, 3 and 4, exhibit in vitro degradation and cytotoxicity comparable with that of 1, and ADC 3 can achieve more sustained in vivo degradation than intravenously administered 1 with markedly reduced systemic exposure of the payload.
Collapse
Affiliation(s)
- Alan Zhang
- Global Discovery Chemistry, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| | - Katherine Seiss
- Oncology Biotherapeutics, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| | - Laurent Laborde
- Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Sebastian Palacio-Ramirez
- Novartis Biologics Center, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| | - Daniel Guthy
- Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Mylene Lanter
- Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Julien Lorber
- Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Anna Vulpetti
- Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Luca Arista
- Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Thomas Zoller
- Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | | | - Claudio Thoma
- Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Christina Hebach
- Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - William R Tschantz
- Novartis Biologics Center, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| | - Alexei Karpov
- Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | | | - Joseph A D'Alessio
- Oncology Biotherapeutics, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| | | | - Matthew T Burger
- Global Discovery Chemistry, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| |
Collapse
|
2
|
Ullrich T, Arista L, Weiler S, Teixeira-Fouchard S, Broennimann V, Stiefl N, Head V, Kramer I, Guth S. Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva. Bioorg Med Chem Lett 2022; 64:128667. [PMID: 35276359 DOI: 10.1016/j.bmcl.2022.128667] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 03/03/2022] [Accepted: 03/07/2022] [Indexed: 11/28/2022]
Abstract
Inhibition of mutant activin A type-1 receptor ACVR1 (ALK2) signaling by small-molecule drugs is a promising therapeutic approach to treat fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease leading to progressive soft tissue heterotopic ossification with no curative treatment available to date. Here, we describe the synthesis and in vitro characterization of a novel series of 2-aminopyrazine-3-carboxamides that led to the discovery of Compound 23 showing excellent biochemical and cellular potency, selectivity over other BMP and TGFβ signaling receptor kinases, and a favorable in vitro ADME profile.
Collapse
Affiliation(s)
- Thomas Ullrich
- Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel CH-4002, Switzerland.
| | - Luca Arista
- Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel CH-4002, Switzerland
| | - Sven Weiler
- Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel CH-4002, Switzerland
| | | | - Valérie Broennimann
- Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel CH-4002, Switzerland
| | - Nikolaus Stiefl
- Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel CH-4002, Switzerland
| | - Victoria Head
- Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel CH-4002, Switzerland
| | - Ina Kramer
- Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel CH-4002, Switzerland
| | - Sabine Guth
- Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel CH-4002, Switzerland
| |
Collapse
|
3
|
O'Connor M, Lucas M, Romashko D, Rasmussen S, Lin TA, Waters N, Fiorenza R, Wrona I, Chen D, Nicolaides T, Raleigh DR, Ozawa T, Trainor G, Arista L, Flohr A, Ottaviani G, Roberts C, Buck E. Abstract LB140: CNS penetrant, irreversible inhibitors potently inhibit the family of allosteric oncogenic EGFR mutants expressed in GBM and demonstrate efficacy in patient-derived xenograft models. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-lb140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Oncogenic EGFR mutations occur in approximately 50% of glioblastomas (GBM) and largely reside in the extracellular domain. Prior attempts to reposition current generation EGFR inhibitors to treat GBM likely failed due to poor brain penetration and an inability to potently target the full spectrum of oncogenic mutations. As EGFR oncogenic mutations are found to be co-expressed in many GBMs, it is important that an inhibitor be broadly active against the entire family of relevant EGFR mutants. Additionally, a successful inhibitor would require a pharmacokinetic (PK) profile that allows for sufficient penetration of the blood brain barrier to elicit robust target engagement of the brain tumor. Using these design principles, we designed a series of highly potent molecules exemplified by BDTX-507. This molecule is an irreversible inhibitor of EGFR with antiproliferative IC50's less than 10 nM against the spectrum of GBM-relevant EGFR mutations. PK/PD studies demonstrated sustained pERK suppression exceeding 24 hours following a single QD dose. Furthermore, when dosed in GBM xenografts, including an intracranial Viii PDX (GBM6), robust tumor regressions and improved survival were observed. Emerging from this series were two advanced compounds, BDTX-700 and BDTX-1535, which also demonstrated potent inhibition of the GBM EGFR spectrum, selectivity v. wild-type EGFR, and an excellent CNS PK profile. BDTX-1535 is currently being evaluated in IND-enabling studies for future clinical evaluation in GBM patients.
Citation Format: Matthew O'Connor, Matt Lucas, Darlene Romashko, Sara Rasmussen, Tai-An Lin, Nigel Waters, Raffaele Fiorenza, Iwona Wrona, Deborah Chen, Theodore Nicolaides, David R. Raleigh, Tomoko Ozawa, George Trainor, Luca Arista, Alexander Flohr, Giorgio Ottaviani, Chris Roberts, Elizabeth Buck. CNS penetrant, irreversible inhibitors potently inhibit the family of allosteric oncogenic EGFR mutants expressed in GBM and demonstrate efficacy in patient-derived xenograft models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB140.
Collapse
Affiliation(s)
| | - Matt Lucas
- 2Black Diamond Therapeutics, Cambridge, MA
| | | | | | - Tai-An Lin
- 3Black Diamond Therapeutics, New York, NY
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
O’Connor M, Lucas M, Romashko D, Rasmussen S, Fiorenza R, Lin TA, Waters N, Trainor G, Flohr A, Ottaviani G, Roberts C, Buck E, Nicolaides T, Raleigh D, Ozawa T, Arista L. EXTH-59. POTENT, SELECTIVE, AND BRAIN PENETRANT INHIBITORS OF EXTRACELLULAR DOMAIN EGFR ONCOGENIC MUTANTS EXPRESSED IN GBM DEMONSTRATE EFFICACY IN AN INTRACRANIAL PATIENT DERIVED XENOGRAFT MODEL. Neuro Oncol 2020. [DOI: 10.1093/neuonc/noaa215.413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
EGFR mutations identified in glioblastomas (GBM) occur nearly exclusively at the allosteric extracellular domain (ECD) and constitutively activate oncogenic signaling. Despite wide success in treating tumors expressing EGFR catalytic site mutants, no drug has demonstrated clinical utility against tumors expressing the extracellular domain EGFR mutants. We demonstrate that the family of ECD mutations are not only co-expressed in GBM, but that they all activate the oncogene through a similar disulfide bond-mediated receptor dimerization mechanism. This dimerization occurs independent of ligands and renders the Locked-dimer (LoDi)-EGFR insensitive to agents that target the EGFR kinase domain mutants in NSCLC. The kinase conformation induced by these ECD mutations seen in glioblastomas is both oncogenic and altered from kinase domain mutations, thus necessitating a new approach to targeting. By screening against cells expressing LoDi-EGFR mutants, we have identified the first inhibitors that potently and selectively target LoDi-EGFR mutants versus both canonical active site oncogenic mutants and wild type EGFR. Through an optimization effort, we have identified a novel family of potent and selective LoDi-EGFR mutant inhibitors that effectively penetrate the blood brain barrier (BBB) following oral dosing in preclinical studies. A leading exemplar, BDTX-GBM-001, inhibits the 5 major LoDi-EGFR mutants expressed in GBM with antiproliferative potency of ~10 nM while showing favorable selectivity versus the human kinome. When dosed orally in the intracranial GBM6 patient derived xenograft model at 50, 30, and 15 mg/kg, a dose responsive decrease in tumor growth, as well as a statistically significant increase in survival, were observed. These data support the continued evaluation of rationally designed BBB penetrant inhibitors selectively targeting the common LoDi-EGFR mutants and enable the first chance to fully test the clinical hypothesis of EGFR driver mutants in GBM.
Collapse
Affiliation(s)
| | - Matt Lucas
- Black Diamond Therapeutics, Cambridge, MA, USA
| | | | | | | | - Tai-An Lin
- Black Diamond Therapeutics, New York City, NY, USA
| | | | | | | | | | | | | | - Theodore Nicolaides
- Division of Pediatric Neuro-Oncology, Department of Pediatrics, NYU Grossman School of Medicine, NYU Langone Health, New York, NY, USA
| | - David Raleigh
- University of California, San Francisco, San Francisco, CA, USA
| | - Tomoko Ozawa
- University of California, San Francisco, San Francisco, CA, USA
| | | |
Collapse
|
5
|
Massaro M, Buscemi G, Arista L, Biddeci G, Cavallaro G, D’Anna F, Di Blasi F, Ferrante A, Lazzara G, Rizzo C, Spinelli G, Ullrich T, Riela S. Multifunctional Carrier Based on Halloysite/Laponite Hybrid Hydrogel for Kartogenin Delivery. ACS Med Chem Lett 2019; 10:419-424. [PMID: 30996773 PMCID: PMC6466553 DOI: 10.1021/acsmedchemlett.8b00465] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2018] [Accepted: 10/22/2018] [Indexed: 12/14/2022] Open
Abstract
A novel carrier system based on halloysite nanotubes (HNT), for the potential intraarticular delivery of kartogenin (KGN) by means laponite (Lap) hydrogel (HNT/KGN/Lap), is developed. The drug was first loaded into HNT, and the hybrid composite obtained was used as filler for laponite hydrogel. Both the filler and the hydrogel were thoroughly investigated by several techniques and the hydrogel morphology was imaged by transmission electron microscopy. Furthermore, the gelating ability of laponite in the presence of the filler and the rheological properties of the hybrid hydrogel were also investigated. The kinetic release of kartogenin from HNT and HNT/Lap hybrid hydrogel was studied both in physiological conditions and in ex vivo synovial fluid. In the last case, the kinetic results highlighted that HNT carrier can effectively release KGN in a sustained manner for at least 38 days. Finally, a preliminary biological assays showed that the HNT/KGN/Lap hybrid hydrogel did not exhibit any cytotoxic effect.
Collapse
Affiliation(s)
- Marina Massaro
- Dipartimento
STEBICEF, Sez. Chimica, Università
degli Studi di Palermo, Viale delle Scienze, Ed. 17, 90128 Palermo, Italy
| | - Gabriella Buscemi
- Dipartimento
STEBICEF, Sez. Chimica, Università
degli Studi di Palermo, Viale delle Scienze, Ed. 17, 90128 Palermo, Italy
| | - Luca Arista
- Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, CH-4002 Basel, Switzerland
| | - Giuseppa Biddeci
- Dipartimento
STEBICEF, Sez. Chimica, Università
degli Studi di Palermo, Viale delle Scienze, Ed. 17, 90128 Palermo, Italy
- Istituto
di Biomedicina ed Immunologia Molecolare - Consiglio Nazionale delle
Ricerche, Via Ugo La
Malfa 153, 90146 Palermo, Italy
| | - Giuseppe Cavallaro
- Dipartimento
di Fisica e Chimica, Università degli
Studi di Palermo, Viale
delle Scienze, Ed. 17, 90128 Palermo, Italy
| | - Francesca D’Anna
- Dipartimento
STEBICEF, Sez. Chimica, Università
degli Studi di Palermo, Viale delle Scienze, Ed. 17, 90128 Palermo, Italy
| | - Francesco Di Blasi
- Istituto
di Biomedicina ed Immunologia Molecolare - Consiglio Nazionale delle
Ricerche, Via Ugo La
Malfa 153, 90146 Palermo, Italy
| | - Angelo Ferrante
- Dipartimento
Biomedico di Medicina Interna e Specialistica, Sezione di Reumatologia, Università degli Studi di Palermo, 90128 Palermo, Italy
| | - Giuseppe Lazzara
- Dipartimento
di Fisica e Chimica, Università degli
Studi di Palermo, Viale
delle Scienze, Ed. 17, 90128 Palermo, Italy
| | - Carla Rizzo
- Dipartimento
STEBICEF, Sez. Chimica, Università
degli Studi di Palermo, Viale delle Scienze, Ed. 17, 90128 Palermo, Italy
| | - Gaetano Spinelli
- Istituto
di Biomedicina ed Immunologia Molecolare - Consiglio Nazionale delle
Ricerche, Via Ugo La
Malfa 153, 90146 Palermo, Italy
| | - Thomas Ullrich
- Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, CH-4002 Basel, Switzerland
| | - Serena Riela
- Dipartimento
STEBICEF, Sez. Chimica, Università
degli Studi di Palermo, Viale delle Scienze, Ed. 17, 90128 Palermo, Italy
| |
Collapse
|
6
|
Kallen J, Izaac A, Be C, Arista L, Orain D, Kaupmann K, Guntermann C, Hoegenauer K, Hintermann S. Structural States of RORγt: X-ray Elucidation of Molecular Mechanisms and Binding Interactions for Natural and Synthetic Compounds. ChemMedChem 2017; 12:1014-1021. [PMID: 28590087 DOI: 10.1002/cmdc.201700278] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2017] [Revised: 06/07/2017] [Indexed: 12/11/2022]
Abstract
The T-cell-specific retinoic acid receptor (RAR)-related orphan receptor-γ (RORγt) is a key transcription factor for the production of pro-inflammatory Th17 cytokines, which are implicated in the pathogenesis of autoimmune diseases. Over the years, several structurally diverse RORγt inverse agonists have been reported, but combining high potency and good physicochemical properties has remained a challenging task. We recently reported a new series of inverse agonists based on an imidazopyridine core with good physicochemical properties and excellent selectivity. Herein we report eight new X-ray crystal structures for different classes of natural and synthetic compounds, including examples selected from the patent literature. Analysis of their respective binding modes revealed insight into the molecular mechanisms that lead to agonism, antagonism, or inverse agonism. We report new molecular mechanisms for RORγt agonism and propose a separation of the inverse agonists into two classes: those that act via steric clash and those that act via other mechanisms (for the latter, co-crystallization with a co-activator peptide and helix 12 in the agonist position is still possible). For the non-steric clash inverse agonists, we propose a new mechanism ("water trapping") which can be combined with other mechanisms (e.g., close contacts with H479). In addition, we compare the interactions made for selected compounds in the "back pocket" near S404 and in the "sulfate pocket" near R364 and R367. Taken together, these new mechanistic insights should prove useful for the design and optimization of further RORγt modulators.
Collapse
Affiliation(s)
- Joerg Kallen
- CBT, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Aude Izaac
- CBT, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Celine Be
- CBT, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Luca Arista
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - David Orain
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Klemens Kaupmann
- ATI, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Christine Guntermann
- ATI, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Klemens Hoegenauer
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Samuel Hintermann
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| |
Collapse
|
7
|
van der Westhuyzen R, Winks S, Wilson CR, Boyle GA, Gessner RK, Soares de Melo C, Taylor D, de Kock C, Njoroge M, Brunschwig C, Lawrence N, Rao SPS, Sirgel F, van Helden P, Seldon R, Moosa A, Warner DF, Arista L, Manjunatha UH, Smith PW, Street LJ, Chibale K. Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration. J Med Chem 2015; 58:9371-81. [PMID: 26551248 DOI: 10.1021/acs.jmedchem.5b01542] [Citation(s) in RCA: 64] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
High-throughput screening of a library of small polar molecules against Mycobacterium tuberculosis led to the identification of a phthalimide-containing ester hit compound (1), which was optimized for metabolic stability by replacing the ester moiety with a methyl oxadiazole bioisostere. A route utilizing polymer-supported reagents was designed and executed to explore structure-activity relationships with respect to the N-benzyl substituent, leading to compounds with nanomolar activity. The frontrunner compound (5h) from these studies was well tolerated in mice. A M. tuberculosis cytochrome bd oxidase deletion mutant (ΔcydKO) was hyper-susceptible to compounds from this series, and a strain carrying a single point mutation in qcrB, the gene encoding a subunit of the menaquinol cytochrome c oxidoreductase, was resistant to compounds in this series. In combination, these observations indicate that this novel class of antimycobacterial compounds inhibits the cytochrome bc1 complex, a validated drug target in M. tuberculosis.
Collapse
Affiliation(s)
- Renier van der Westhuyzen
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Susan Winks
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Colin R Wilson
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Grant A Boyle
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Richard K Gessner
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Candice Soares de Melo
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Dale Taylor
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Observatory 7925, South Africa
| | - Carmen de Kock
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Observatory 7925, South Africa
| | - Mathew Njoroge
- South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Christel Brunschwig
- South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Nina Lawrence
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Srinivasa P S Rao
- Novartis Institute for Tropical Diseases (NITD) , 10 Biopolis Road, Chromos no. 05-01, Singapore 138670, Singapore
| | - Frederick Sirgel
- DST/NRF Centre of Excellence in Biomedical TB Research, SA MRC Centre for TB Research, Division of Molecular Biology and Human Genetics, Faculty of Health Sciences, Stellenbosch University , Tygerberg 7505, South Africa
| | - Paul van Helden
- DST/NRF Centre of Excellence in Biomedical TB Research, SA MRC Centre for TB Research, Division of Molecular Biology and Human Genetics, Faculty of Health Sciences, Stellenbosch University , Tygerberg 7505, South Africa
| | - Ronnett Seldon
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Atica Moosa
- MRC/NHLS/UCT Molecular Mycobacteriology Research Unit, Department of Pathology, University of Cape Town , Rondebosch 7701, South Africa
| | - Digby F Warner
- MRC/NHLS/UCT Molecular Mycobacteriology Research Unit, Department of Pathology, University of Cape Town , Rondebosch 7701, South Africa.,Institute of Infectious Disease and Molecular Medicine, University of Cape Town , Rondebosch 7701, South Africa
| | - Luca Arista
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , Novartis Campus, CH-4056 Basel, Switzerland
| | - Ujjini H Manjunatha
- Novartis Institute for Tropical Diseases (NITD) , 10 Biopolis Road, Chromos no. 05-01, Singapore 138670, Singapore
| | - Paul W Smith
- Novartis Institute for Tropical Diseases (NITD) , 10 Biopolis Road, Chromos no. 05-01, Singapore 138670, Singapore
| | - Leslie J Street
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Kelly Chibale
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa.,South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa.,Institute of Infectious Disease and Molecular Medicine, University of Cape Town , Rondebosch 7701, South Africa
| |
Collapse
|
8
|
Högenauer K, Arista L, Schmiedeberg N, Werner G, Jaksche H, Bouhelal R, Nguyen DG, Bhat BG, Raad L, Rauld C, Carballido JM. G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) agonists reduce the production of proinflammatory cytokines and stabilize the alternative macrophage phenotype. J Med Chem 2014; 57:10343-54. [PMID: 25411721 DOI: 10.1021/jm501052c] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
GPBAR1 (also known as TGR5) is a G-protein-coupled receptor (GPCR) that triggers intracellular signals upon ligation by various bile acids. The receptor has been studied mainly for its function in energy expenditure and glucose homeostasis, and there is little information on the role of GPBAR1 in the context of inflammation. After a high-throughput screening campaign, we identified isonicotinamides exemplified by compound 3 as nonsteroidal GPBAR1 agonists. We optimized this series to potent derivatives that are active on both human and murine GPBAR1. These agonists inhibited the secretion of the proinflammatory cytokines TNF-α and IL-12 but not the antiinflammatory IL-10 in primary human monocytes. These effects translate in vivo, as compound 15 inhibits LPS induced TNF-α and IL-12 release in mice. The response was GPBAR1 dependent, as demonstrated using knockout mice. Furthermore, agonism of GPBAR1 stabilized the phenotype of the alternative, noninflammatory, M2-like type cells during differentiation of monocytes into macrophages. Overall, our results illustrate an important regulatory role for GPBAR1 agonists as controllers of inflammation.
Collapse
Affiliation(s)
- Klemens Högenauer
- Global Discovery Chemistry, ‡Autoimmunity, Transplantation and Inflammation, and §Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research , Novartis Campus, CH-4056 Basel, Switzerland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Micheli F, Arista L, Bertani B, Braggio S, Capelli AM, Cremonesi S, Di-Fabio R, Gelardi G, Gentile G, Marchioro C, Pasquarello A, Provera S, Tedesco G, Tarsi L, Terreni S, Worby A, Heidbreder C. Exploration of the Amine Terminus in a Novel Series of 1,2,4-Triazolo-3-yl-azabicyclo[3.1.0]hexanes as Selective Dopamine D3 Receptor Antagonists. J Med Chem 2010; 53:7129-39. [DOI: 10.1021/jm100832d] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Fabrizio Micheli
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Luca Arista
- Novartis Institute Research, Basel, Switzerland
| | - Barbara Bertani
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Simone Braggio
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Anna Maria Capelli
- Molecular Discovery Research
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Susanna Cremonesi
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Romano Di-Fabio
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Giacomo Gelardi
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Gabriella Gentile
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Carla Marchioro
- Molecular Discovery Research
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Alessandra Pasquarello
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Stefano Provera
- Molecular Discovery Research
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Giovanna Tedesco
- Molecular Discovery Research
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Luca Tarsi
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Silvia Terreni
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | | | | |
Collapse
|
10
|
Micheli F, Arista L, Bonanomi G, Blaney FE, Braggio S, Capelli AM, Checchia A, Damiani F, Di-Fabio R, Fontana S, Gentile G, Griffante C, Hamprecht D, Marchioro C, Mugnaini M, Piner J, Ratti E, Tedesco G, Tarsi L, Terreni S, Worby A, Ashby CR, Heidbreder C. 1,2,4-Triazolyl Azabicyclo[3.1.0]hexanes: A New Series of Potent and Selective Dopamine D3 Receptor Antagonists. J Med Chem 2009; 53:374-91. [DOI: 10.1021/jm901319p] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Fabrizio Micheli
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Luca Arista
- Novartis Institute Research, Basel, Switzerland
| | - Giorgio Bonanomi
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Frank E. Blaney
- Molecular Discovery Research
- GlaxoSmithKline Medicines Research Centre, NFSP, Harlow, U.K
| | - Simone Braggio
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Anna Maria Capelli
- Molecular Discovery Research
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Anna Checchia
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | | | - Romano Di-Fabio
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Stefano Fontana
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Gabriella Gentile
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Cristiana Griffante
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | | | - Carla Marchioro
- Molecular Discovery Research
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Manolo Mugnaini
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Jacqui Piner
- Safety Assessment
- GlaxoSmithKline Medicines Research Centre, NFSP, Harlow, U.K
| | - Emiliangelo Ratti
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, NFSP, Harlow, U.K
| | - Giovanna Tedesco
- Molecular Discovery Research
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Luca Tarsi
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Silvia Terreni
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Angela Worby
- Molecular Discovery Research
- GlaxoSmithKline Medicines Research Centre, NFSP, Harlow, U.K
| | - Charles R. Ashby
- Department of Pharmaceutical Sciences, Saint John’s University, Jamaica, New York 11439
| | | |
Collapse
|
11
|
|
12
|
Arista L, Gruttadauria M, Thomas E. Stereoselective Synthesis of cis-2,5-Disubstituted Tetrahydrofurans: An Approach to Pamamycins. Synlett 1997. [DOI: 10.1055/s-1997-3219] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
13
|
Palombi L, Arista L, Lattanzi A, Bonadies F, Scettri A. Zeolite-catalyzed oxidation of benzylic and acetylenic alcohols with t-butyl hydroperoxide. Tetrahedron Lett 1996. [DOI: 10.1016/0040-4039(96)01747-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
14
|
|